research centers


Search results: Found 3

Listing 1 - 3 of 3
Sort by

Article
Interleukin (IL) 17 expression in Iraqi bladder carcinoma Patients

Author: Hind M. Mousa
Journal: Iraqi Journal of Biotechnology المجلة العراقية للتقانات الحياتية ISSN: 18154794 Year: 2017 Volume: 16 Issue: 3 Pages: 94-97
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Interleukin (IL- 17) is pro inflammatory cytokines produced by CD4+ T-helper17 (Th17)cell .It has a vital effect on cells of the immune system playing crucial roles in pathogenesis of immune-mediated diseases, like-cancers. The current study was designed to detect the protein expression of IL-17 in Iraqi bladder carcinoma patients, and its correlation with clinical grades. Tissue samples were collected from 45 patients with bladder carcinoma. The immunoexpression of IL-17 was detected by using IL-17 monoclonal antibody. The results of Immunohistochemical (IHC) studying showed that tissues with positive (IL-17) expression were low in bladder cancer patients practically in low grades with significant difference, it is concluded that IL-17 expression can be used as indicators for procession in bladder cancer.

Keywords

IL-17 --- Bladder Cancer --- IHC --- Carcinoma .


Article
The Endoglin (CD105) Expression as a Marker of Tumour Vasculature in Urinary Bladder Tumours of Iraqi patients

Authors: Hind M. Mousa --- Amna N. Jassem --- Munther J. Hussain
Journal: Mesopotamia Environmental Journal بيئة وادي الرافدين ISSN: 24102598 Year: 2017 Issue: Special Issue C Pages: 93-98
Publisher: Babylon University جامعة بابل

Loading...
Loading...
Abstract

The Endoglin CD105 is a good marker for metastatic in solid tumors . It has a role in angiogenesis process which mediates blood vessels formation. The aim of this study to evaluate CD105 immunoexpressions in bladder tumors, and to determine its relation with clinico-pathological grades in patients with UBC . The study included 50 biopsies from patients with urinary bladder carcinoma (UBC) and 15- benign bladder biopsies from patients with other bladder disorders rather than cancer (UBD). CD105 immunostaining was assessed using Envision method . Immunohistochemical (IHC) studying showed that (CD105) proteins were significantly high expressed in UBC compared with UBD patients (80% vs. 33.3 % ; p≤ 0.01) , and there was significant difference in the positive IHC results of this protein in correlation to clinico-pathological grades in UBC patients (p≤ 0.01) . we conclude that CD105 IHC expressionin bladder cancer may be consider as prognostic marker .


Article
A Comparative Study Between Single Session Versus Six Sessions Mitomycin C instillation in Patients With Low Risk Non-Muscle Invasive Bladder Cancer

Author: Saad Dakhil F. Daraji*,Zaidan khalaf**
Journal: Iraqi Academic Scientific Journal المجلة العراقية للاختصاصات الطبية ISSN: 16088360 Year: 2017 Volume: 16 Issue: 2 Pages: 158-163
Publisher: The Iraqi Borad for Medical Specialization المجلس العراقي للاختصاصات الطبية

Loading...
Loading...
Abstract

ABSTRACT:BACKGROUND: Intra vesicle instillation following trans uretheral resection of low grade and low stage bladder cancer proved its efficacy in reducing recurrence and progression of bladder cancer.OBJECTIVE:To compare the efficacy of a single session of mitomycine C versus six sessions mitomycine C following TURBT on recurrence and progression rates in patients with low risk non-muscle invasive bladder cancer.PATIENTS AND METHODS:A total of 50 patients with low risk non-invasive bladder cancer were included in a prospective randomized controlled trial. Inclusion criteria include all patients who had a 3cm or less, single, papillary tumor. The tumor was completely resected before were randomized patients into 2 arms; Group one; those who receiving one session mitomycin C instillation of 40 mg (usually within 6 hours) into the urinary bladder. And Group B; Receiving six sessions mitomycin C instillation into the urinary bladder, Median follow up was 24 months. The events studied where the recurrence free rate, the recurrence rate/ year, the number of new tumors developing/year, and progression. RESULTS:At 24 months follow up, the recurrence free rate in a single session of mitomycin C instillation (group A) was (70.2%) while in six sessions mitomycin C instillation group was (84.7%) (Group B). Recurrence rate was ; Group A VS Group B : (10% VS 4 %) and recurrence per year rate (5% VS 2%), were decreased in the six sessions mitomycin C instillation (Group B) compared to the single session mitomycin C instillation (Group A). The number of new tumors per year rate (18% VS 11%), were decreased in the six sessions mitomycin C instillation (Group B) compared to the one session mitomycin C instillation, (Group A). A shorter hospital stay, catheterization period, and low level of local symptoms were noted in one session mitomycin C instillation (Group A) compared to six sessions mitomycin C instillation, (Group B). CONCLUSION:Single session mitomycin C given immediately after surgery or within 6 hours after resection may be as effective as six session protocol. This regimen may be cost effective and avoid prolonged hospitalization and catheterization with sex sessions regimen.

Listing 1 - 3 of 3
Sort by
Narrow your search

Resource type

article (3)


Language

English (3)


Year
From To Submit

2017 (3)